• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award

Posted on: Tuesday, 24 February 2009, 05:00 CST

BOSTON, Feb. 24 /PRNewswire-FirstCall/ -- Perceptive Informatics, the industry's leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today announced that it has received the Frost & Sullivan Product Line Strategy Award. Frost & Sullivan presented the award to Perceptive Informatics in recognition of its commitment to excel in the field of clinical technology solutions.

The Frost & Sullivan Product Line Strategy Award recognizes Perceptive Informatics for demonstrating insight into the needs and product demands of its customers. The award acknowledges the work that Perceptive Informatics has done to optimize its product line by leveraging products with the various price, performance, and feature points required by one or more market segments. Frost & Sullivan honored Perceptive Informatics for successfully conceiving and evolving a product portfolio that has wide influence on the drug development process.

"We are honored to receive the Product Line Strategy Award from Frost & Sullivan," said Steve Kent, President of Perceptive Informatics. "This important recognition reinforces our continued focus on technology innovation, commitment to improving clinical trial workflow and enhanced customer support. Our goal is to provide industry-leading eClinical technology capabilities to help clients improve the efficiency and productivity of their clinical studies."

The comprehensive product portfolio provided by Perceptive Informatics includes Interactive Voice and Web Response Systems (IVRS/IWRS), Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions. Perceptive Informatics also provides eClinical systems integration and implementation services.

Frost & Sullivan, a global growth consulting company, tracks companies across various industries worldwide. For information about Frost & Sullivan and its Best Practices Program visit www.frost.com.

About Perceptive Informatics

Perceptive Informatics, a subsidiary of PAREXEL, is the industry's leading eClinical solutions provider. Perceptive Informatics offers unprecedented access to innovative eClinical technologies and resources, providing clinical trial sponsors, CROs, and other service providers with the benefits of an extensive line of products and services throughout the entire clinical development lifecycle. In August 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers best-in-class eClinical software and services that increase the efficiency and productivity of clinical research. Perceptive's expansive product portfolio includes Interactive Voice and Web Response Systems (IVRS/IWRS), Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information about Perceptive Informatics, visit www.perceptive.com.

About PAREXEL

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has more than 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

Contacts: Jennifer Baird, Senior Director of Public Relations PAREXEL International Tel: +781-434-4409 Email: Jennifer.Baird@PAREXEL.com Rebecca Passo SHIFT Communications Tel: +617-779-1817 Email: rpasso@shiftcomm.com

SOURCE PAREXEL International Corporation

Source: PR Newswire

More News in this Category